Pulmonary alveolar hemorrhage following thrombolytic therapy

Santhosh Narayanan¹
NK Thulaseedharan¹
Gomathy Subramaniam²
Geetha Panarkandy¹
Narayanan Arathi¹
¹Department of Medicine, ²Department of Radiodiagnosis, Government Medical College, Kozhikode, Kerala, India

Abstract: We report a case of a 58-year-old male without any comorbidities who was thrombolysed with streptokinase for acute anterior wall myocardial infarction and developed massive hemoptysis with dyspnea and imaging features showing bilateral alveolar infiltrates. He was diagnosed with pulmonary alveolar hemorrhage and treated conservatively. His condition improved, and follow-up imaging showed resolution. Alveolar hemorrhage is a rare and life-threatening complication of thrombolytic therapy.

Keywords: hemoptysis, alveolar hemorrhage

Case report
A 58-year-old male without any past history of comorbid illness or addictions presented to our emergency department with a history of left-sided constricting chest pain with excessive sweating for 1 hour duration. On examination, he was anxious with a pulse rate of 108/min, regular in rhythm blood pressure (BP) of 120/80 mmHg and respiratory rate of 16/min. Systemic examination was unremarkable. Electrocardiogram was suggestive of anterior wall myocardial infarction, with ST elevation in V1–V4 and ST depression in leads 1 and aVL. Echocardiogram demonstrated regional wall motion abnormality in the anterior wall. He was initially loaded with aspirin and clopidogrel. He was thrombolysed with 1.5 million units of streptokinase. His chest pain subsided, and electrocardiogram taken 90 minutes after thrombolysis showed good ST resolution. After 6 hours, he developed massive hemoptysis and breathlessness. His oxygen saturation in room air fell to 86% from an initial value of 99%. Examination revealed bilateral fine-end inspiratory crepitations in all lung fields. His jugular venous pressure was normal, and there were no signs of heart failure. A chest X-ray (Figure 1) revealed bilateral alveolar infiltrates. High-resolution computed tomography (HRCT) of thorax (Figure 2) confirmed the presence of alveolar hemorrhage. Hemoglobin fell from 14 to 10 g/dL. He had no other bleeding manifestations. He was treated with oxygen and blood transfusion. Diffusion lung capacity for carbon monoxide was markedly elevated. His condition improved symptomatically with treatment. After 1 week, his oxygen saturation in room air was 98% and his lung fields were normal on auscultation. A chest X-ray taken after 10 days showed resolution of lesions (Figure 3). The tests for anti-glomerular basement membrane antibodies, antinuclear antibodies, anti-double-stranded deoxyribonucleic acid antibodies, peripheral anti-neutrophil cytoplasmic antibodies (p-ANCAs) and cytoplasmic ANCAs showed negative results. Toxicology screening and retroviral screening were negative. On follow-up after 1 month,
pulmonary function tests, including diffusion lung capacity for carbon monoxide, were done, which were reported as normal. He was restarted on clopidogrel after 3 months and is asymptomatic till date.

**Discussion**

Thrombolytic therapy for myocardial infarction can result in hemorrhagic complications, the most common being bleeding from vascular access sites. Pulmonary alveolar hemorrhage is an uncommon and life-threatening complication of fibrinolytic therapy and should be considered as one of the differential diagnoses of pulmonary infiltrates or a decreasing level of hemoglobin after thrombolysis. There are no data regarding the exact incidence of this complication, except for a few case reports. It usually develops within a few hours to 5 days after thrombolysis. Some predisposing factors include immunodeficiency, pneumonia, chronic obstructive pulmonary disease, congestive heart failure and cocaine and tobacco.
abuse. Pathogenesis of alveolar hemorrhage following thrombolysis is incompletely understood, and the exact mechanism is not yet elucidated.\textsuperscript{3,4} Other causes of pulmonary alveolar hemorrhage include acute respiratory distress syndrome, pulmonary renal syndrome, idiopathic pulmonary capillaritis and connective tissue diseases.\textsuperscript{5} Ikeda et al\textsuperscript{6} reported a case in which alveolar hemorrhage occurred following dual antiplatelet therapy. Clinically, pulmonary alveolar hemorrhage presents as a triad of hemoptyisis, diffuse alveolar opacities in chest radiography and anemia. Many cases do not exhibit this classical triad, but alveolar hemorrhage should be suspected when at least two of them are present. Hemoptyisis may not be evident in a few cases, because of the distal location of the bleeding source.\textsuperscript{7} Dyspnea results from both ventilation/perfusion mismatch secondary to alveolar filling and anemia. Chest radiography usually shows bilateral symmetrical opacities and alveolar opacities. Rarely, there may be consolidation with air bronchogram or multiple nodules reflecting acinar filling. Pulmonary apices and costodiaphragmatic angles are spared. HRCT shows ground-glass opacities or consolidation, with predominantly central involvement and relative sparing of the lung periphery.\textsuperscript{8} At a later stage, alveolar opacities are replaced by more reticular opacities and micronodules, reflecting hemorrhage resorption in the pulmonary interstitium. An increase in diffusing capacity of the lung for carbon monoxide is attributed to increased carbon monoxide uptake by intra-alveolar red blood cells. A macroscopically hemorrhagic bronchoalveolar lavage (BAL) fluid is considered diagnostic of acute alveolar hemorrhage.\textsuperscript{9} After a bleeding episode, hemoglobin is converted into hemosiderin by alveolar macrophages in 36–72 hours. Hemosiderin-laden macrophages reside in the lungs for 4–8 weeks.\textsuperscript{10} Management consists of treatment of respiratory failure with supplemental oxygen and mechanical ventilation, if needed. Instances with severe anemia due to rapid decline in hemoglobin should be corrected with packed cell transfusion.\textsuperscript{11}

**Informed consent**

Written informed consent was obtained from the patient for the publication of this report and accompanying images.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


